"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 6 | 6 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 11 | 11 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 12 | 12 |
| 2001 | 0 | 16 | 16 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 14 | 14 |
| 2004 | 0 | 18 | 18 |
| 2005 | 0 | 11 | 11 |
| 2006 | 0 | 15 | 15 |
| 2007 | 0 | 19 | 19 |
| 2008 | 0 | 32 | 32 |
| 2009 | 0 | 25 | 25 |
| 2010 | 0 | 25 | 25 |
| 2011 | 0 | 34 | 34 |
| 2012 | 0 | 35 | 35 |
| 2013 | 0 | 39 | 39 |
| 2014 | 0 | 49 | 49 |
| 2015 | 0 | 53 | 53 |
| 2016 | 0 | 63 | 63 |
| 2017 | 0 | 59 | 59 |
| 2018 | 0 | 40 | 40 |
| 2019 | 0 | 33 | 33 |
| 2020 | 0 | 27 | 27 |
| 2021 | 0 | 8 | 8 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 9 | 9 |
| 2024 | 0 | 10 | 10 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia. Am J Hematol. 2025 Jun; 100(6):980-986.
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
-
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
-
15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). J Clin Oncol. 2024 Oct; 42(28):3319-3329.
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 11 07; 391(18):1709-1720.
-
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
-
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10; 42(14):1619-1624.
-
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Gu?rin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Gu?rin Treatment. Clin Genitourin Cancer. 2024 Jun; 22(3):102059.
-
Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease. Leuk Res. 2024 03; 138:107456.
-
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 04; 38(4):720-728.